On November 26, 2020, the Supreme Court of Korea held that generic drug manufacturers were not responsible for damages incurred by an original pharmaceutical company resulting from the automatic price reduction ...
These heightened criminal penalties, however, will not be imposed retroactively on violations that took place prior to the effective date of the amendments.
On December 23, 2015, the Korean Constitutional Court, the final arbiter of constitutional disputes in Korea, issued a pair of companion decisions that clarify the bounds of medical advertisement regulation in Korea.